secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2023-02-03T23:59:59+00:00
Accession:  0001764013-23-000020
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant reports widened Q3 net loss of $63.2M; cash $432.6M; batoclimab trials on track
--------------------------------------------------------------------------------

- Net loss $63.2M ($0.49/share) vs $41.4M ($0.36) prior year; R&D spend rose to $42.3M.
- Cash $432.6M expected to fund operations into second half of calendar 2025.
- Phase 1 trial of IMVT-1402 to start early 2023; initial data expected mid-2023.
- Phase 3 batoclimab in TED initiated; Phase 2b in CIDP started; topline results H1 2025 and H1 2024.
- Batoclimab development for warm AIHA discontinued; indication reserved for IMVT-1402.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401323000020/0001764013-23-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401323000020/imvt-20230203.htm
  HTML page:      https://secwatch.observer/filing/0001764013-23-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer